With so many powerful and important godfathers and the United States president fully committed, it would be unprecedented for FDA to deny authorization to molnupiravir, no matter how disastrous the clinical trial results may be. Merck is so certain of FDA’s approval that by September 2020, it was already scaling up manufacturing, even though its clinical trials are still underway.
